The Role of Osteoclasts in Breast Cancer Bone Metastasis

Overview

Journal J Bone Oncol

Publisher Elsevier

Date 2016 Oct 21

PMID 27761364

Citations 59

Authors

Francois Le Pape

Geoffrey Vargas

Philippe Clezardin

Affiliations

Soon will be listed here.

Abstract

Breast cancer frequently metastasises to the skeleton, interfering with the normal bone remodelling process and inducing bone degradation. Bone degradation is caused by osteoclasts, the normal bone-resorbing cells. Osteoclast-mediated bone degradation subsequently leads to the release of bone-derived factors that promote skeletal tumour growth. Osteoclasts themselves stimulate tumour growth. This Review describes the molecular mechanisms through which osteoclasts and breast cancer cells collaborate with each other, triggering the formation of osteolytic bone metastasis.

Citing Articles

Cannabinoid Receptor Type 2 Agonist, GW405833, Reduced the Impacts of MDA-MB-231 Breast Cancer Cells on Bone Cells.

Inson I, Chutoe C, Kanjanapipak J, Lertsuwan K Cancer Med. 2025; 14(4):e70709.

PMID: 39980332 PMC: 11842928. DOI: 10.1002/cam4.70709.

The role of exosomal non-coding RNAs in the breast cancer tumor microenvironment.

Saadh M, Allela O, Kareem R, Ballal S, Chahar M, Saini S Funct Integr Genomics. 2025; 25(1):32.

PMID: 39891771 DOI: 10.1007/s10142-025-01531-2.

Harnessing curcumin and nanotechnology for enhanced treatment of breast cancer bone metastasis.

Shakori Poshteh S, Alipour S, Varamini P Discov Nano. 2024; 19(1):177.

PMID: 39527354 PMC: 11554965. DOI: 10.1186/s11671-024-04126-1.

Pre-metastatic niche: formation, characteristics and therapeutic implication.

Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q Signal Transduct Target Ther. 2024; 9(1):236.

PMID: 39317708 PMC: 11422510. DOI: 10.1038/s41392-024-01937-7.

[miRNA Is Involved in the Pathogenesis of Multiple Diseases by Targeting Osteoprotegerin].

Zhou D, Yang D Sichuan Da Xue Xue Bao Yi Xue Ban. 2024; 55(3):777-782.

PMID: 38948285 PMC: 11211783. DOI: 10.12182/20240560607.

References

Clement-Demange L, Clezardin P . Emerging therapies in bone metastasis. Curr Opin Pharmacol. 2015; 22:79-86. DOI: 10.1016/j.coph.2015.04.004. View

Mundy G . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2(8):584-93. DOI: 10.1038/nrc867. View

Fradet A, Sorel H, Bouazza L, Goehrig D, Depalle B, Bellahcene A . Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. Cancer Res. 2011; 71(17):5728-38. DOI: 10.1158/0008-5472.CAN-11-1431. View

ODay E, Lal A . MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010; 12(2):201. PMC: 2879559. DOI: 10.1186/bcr2484. View

Clezardin P . Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res. 2011; 13(2):207. PMC: 3219181. DOI: 10.1186/bcr2835. View

Lee D, Deng Z, Wang C, Yang B . MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A. 2007; 104(51):20350-5. PMC: 2154434. DOI: 10.1073/pnas.0706901104. View

Buijs J, Stayrook K, Guise T . The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bonekey Rep. 2013; 1:96. PMC: 3727840. DOI: 10.1038/bonekey.2012.96. View

Lam J, Takeshita S, Barker J, Kanagawa O, Ross F, Teitelbaum S . TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000; 106(12):1481-8. PMC: 387259. DOI: 10.1172/JCI11176. View

Boyce B, Xing L . Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473(2):139-46. PMC: 2413418. DOI: 10.1016/j.abb.2008.03.018. View

10.

Nelson J, Bagnato A, Battistini B, Nisen P . The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003; 3(2):110-6. DOI: 10.1038/nrc990. View

11.

Croset M, Kan C, Clezardin P . Tumour-derived miRNAs and bone metastasis. Bonekey Rep. 2015; 4:688. PMC: 4432779. DOI: 10.1038/bonekey.2015.56. View

12.

Weigelt B, Peterse J, J van t Veer L . Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005; 5(8):591-602. DOI: 10.1038/nrc1670. View

13.

Edwards J, Mundy G . Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol. 2011; 7(4):235-43. DOI: 10.1038/nrrheum.2011.23. View

14.

Cappariello A, Maurizi A, Veeriah V, Teti A . The Great Beauty of the osteoclast. Arch Biochem Biophys. 2014; 558:70-8. DOI: 10.1016/j.abb.2014.06.017. View

15.

Sugatani T, Vacher J, Hruska K . A microRNA expression signature of osteoclastogenesis. Blood. 2011; 117(13):3648-57. PMC: 3072882. DOI: 10.1182/blood-2010-10-311415. View

16.

Sanders J, Chattopadhyay N, Kifor O, Yamaguchi T, Butters R, Brown E . Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology. 2000; 141(12):4357-64. DOI: 10.1210/endo.141.12.7849. View

17.

Weilbaecher K, Guise T, McCauley L . Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011; 11(6):411-25. PMC: 3666847. DOI: 10.1038/nrc3055. View

18.

Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K . Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell. 2013; 24(4):542-56. PMC: 3832956. DOI: 10.1016/j.ccr.2013.09.008. View